{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342463","form_type":"8-K","ticker":"CBLL","cik":"0001861107","company_name":"Ceribell, Inc.","filed_at":"2026-08-10T20:27:00+00:00","discovered_at":"2026-08-10T20:28:00.372137+00:00","generated_at":"2026-08-10T20:28:07.191683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ceribell Q2 revenue up 33% to $28.1M; raises FY2026 guidance to $114-117M","bullets":["Total revenue $28.1M, up 33% YoY; product revenue $21.2M, subscription $6.9M.","Net loss $19.3M ($0.51/share) vs $13.6M loss YoY; adjusted EBITDA loss $9.8M.","Gross margin 92% (up from 88%) on cost cuts, Vietnam line, and tariff refunds.","New $60M credit facility (term loan + revolver) refinances debt; cash $129.3M.","Raised FY2026 revenue guidance to $114-117M (28-31% growth); FDA clearances for algorithms and hardware."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342463","json":"https://secwatch.observer/filing/0001193125-26-342463.json","markdown":"https://secwatch.observer/filing/0001193125-26-342463.md","text":"https://secwatch.observer/filing/0001193125-26-342463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861107/000119312526342463/0001193125-26-342463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861107/000119312526342463/cbll-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:28:07.191683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}